AIA Review Of Wyeth's Tygacil Sought By Drug-Pricing Group

By Aaron Vehling ( August 11, 2014, 3:30 PM EDT) -- Wyeth LLC's patent for Tygacil, a drug based on the antibiotic tigecycline, on Friday entered the sights of a self-proclaimed patients' rights organization, which argued for inter partes review at the U. S. Patent and Trademark Office on the grounds the patent's claims are invalid as obvious. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login